GILD catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04251416A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaYale University · Endometrial CarcinomaActive, not recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT04639986Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Gilead Sciences · Metastatic Breast CancerActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06048133Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)Nataliya Uboha · Biliary Tract CarcinomaActive, not recruitingRCUSCollaboratorGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06082960Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsGilead Sciences · Solid TumorsActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT05675579A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage...M.D. Anderson Cancer Center · Breast CancerActive, not recruitingGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 2027Sponsor estimate | NCT06029972Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisGilead Sciences · Ulcerative Colitis | GILDLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 12, 2027Sponsor estimate | NCT05609968Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With...Merck Sharp & Dohme LLC · Carcinoma, Non-Small-Cell Lung | MRKLeadGILDCollaborator | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple...Laura Huppert, MD, BA · Stage III Breast Cancer | PFECollaboratorGILDCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 2027Sponsor estimatePhase 2NCT06029972Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative ColitisGilead Sciences · Ulcerative ColitisActive, not recruitingGILDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2027Sponsor estimatePhase 3NCT05609968Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With...Merck Sharp & Dohme LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingMRKLeadGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 2NCT03971409Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple...Laura Huppert, MD, BA · Stage III Breast CancerActive, not recruitingPFECollaboratorGILDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.